TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity

Vaccine

Volumn 27, Issue 23, 2009, Pages 3045-3052

  Johnson, Teresa R ^a   Rao, Srinivas ^a   Seder, Robert A ^a   Chen, Man ^a   Graham, Barney S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adjuvant; Eosinophil; Immunization; Pathogenesis; Pathology; RSV; Toll like receptors

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG POTENTIATION; EOSINOPHIL COUNT; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; CELL LINE; GLYCINE; HUMANS; IMIDAZOLES; IMMUNITY, CELLULAR; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTOR 9; VIRULENCE;

EID: 67349253124     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.026     Document Type: Article

References (57)

1. Cardenas S., Auais A., and Piedimonte G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 3 (2005) 719-726
2. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 (2005) 1093-1104
3. Medzhitov R. Toll-like receptors and innate immunity. Nature Rev Immunol 1 (2001) 135-145
4. Kawai T., and Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann NY Acad Sci (2008) 1-20
5. Atkinson T.J. Toll-like receptors, transduction-effector pathways, and disease diversity: evidence of an immunobiological paradigm explaining all human illness?. Int Rev Immunol 27 (2008) 255-281
6. Bowie A.G., and Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8 (2008) 911-922
7. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199 (2004) 227-250
8. Durbin J.E., and Durbin R.K. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol 17 (2004) 370-380
9. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., and Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17 (2007) 5-34
10. Johnson T.R., and Graham B.S. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr Infect Dis J 23 (2004) S46-S57
11. Miyairi I., and Devincenzo J.P. Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev (2008) 686-703
12. Tang Y.-W., and Graham B.S. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus. J Clin Invest 94 (1994) 1953-1958
13. Johnson T.R., Parker R.A., Johnson J.E., and Graham B.S. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 170 (2003) 2037-2045
14. Neuzil K.M., Johnson J.E., Tang Y.-W., Prieels J.P., Slaoui M., Gar N., et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 15 (1997) 525-532
15. Hussell T., Khan U., and Openshaw P.J.M. IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness. J Immunol 159 (1997) 328-334
16. Hancock G.E., Speelman D.J., Heers K., Bortell E., Smith J., and Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 70 (1996) 7783-7791
17. Johnson T.R., Rothenberg M.E., and Graham B.S. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leuk Biol 84 (2008) 748-759
18. Bont L., Versteegh J., Swelsen W.T.M., Heijnen C.J., Kavelaars A., Brus F., et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res 52 (2002) 363-367
19. Hall C.B., Long C.E., and Schnabel K.C. Respiratory syncytial virus infections in previously healthy working adults. Clin Infec Dis 33 (2001) 792-796
20. Valarcher J.-F., Furze J., Wyld S., Cook R., Conzelmann K.-K., and Taylor G. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol 77 (2003) 8426-8439
21. Spann K.M., Tran K.-C., Chi B., Rabin R.L., and Collins P.L. Suppression of the induction of alpha, beta, and gamma interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J Virol 78 (2004) 4363-4369
22. Hancock G.E., Heers K.M., Smith J.D., Scheuer C.A., Igraghimov A.R., and Pryharski K.S. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine 19 (2001) 4874-4882
23. Hancock G.E., Heers K.M., Pryharski K.S., Smith J.D., and Tiberio L. Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21 (2003) 4348-4358
24. Prince G.A., Mond J.J., Porter D.D., Yim K.C., Lan S.J., and Klinman D.M. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 77 (2003) 13156-13160
25. Oumouna M., Mapletoft J.W., Karvonen B.C., Babiuk L.A., and van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 79 (2005) 2024-2032
26. Mapletoft J.W., Oumouna M., Townsend H.G., Gomis S., Babiuk L.A., and van Drunen Littel-van den Hurk S. Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 353 (2006) 316-323
27. Tayyari F., Sutton T.C., Manson H.E., and Hegele R.G. CpG-oligodeoxynucleotides inhibit RSV-enhanced allergic sensitisation in guinea pigs. Eur Respir J 25 (2005) 295-302
28. Graham B.S., Perkins M.D., Wright P.F., and Karzon D.T. Primary respiratory syncytial virus infection in mice. J Med Virol 26 (1988) 153-162
29. Graham B.S., Henderson G.S., Tang Y.-W., Lu X., Neuzil K.M., and Colley D.G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 151 (1993) 2032-2040
30. Wille-Reece U., Wu C., Flynn B.J., Kedl R.M., and Seder R.A. Immunization with HIV-1 gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8+ T cell responses. J Immunol 174 (2005) 7676-7683
31. Johnson T.R., Johnson J.E., Roberts S.R., Wertz G.W., Parker R.A., and Graham B.S. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 72 (1998) 2871-2880
32. Legge K.L., and Braciale T.J. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 18 (2003) 265-277
33. Beyer M., Bartz H., Hörner K., Doths S., Koerner-Rettberg C., and Schwarze J. Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. J Allergy Clin Immunol 113 (2004) 127-133
34. Johnson T.R., and Graham B.S. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73 (1999) 8485-8495
35. Wills-Karp M., and Ewart S.L. The genetics of allergen-induced airway hyperresponsiveness in mice. Am J Resp Crit Care Med 156 (1997) S89-S96
36. Nagase H., Okugawa S., Ota Y., Yamaguchi M., Tomizawa H., Matsushima K., et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 171 (2003) 3977-3982
37. Trevani A.S., Chorny A., Salamone G., Vermeulen M., Gamberale R., Schettini J., et al. Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 33 (2003) 3164-3174
38. Gold M.C., Donnelly E., Cook M.S., Leclair C.M., and Lewinsohn D.A. Purified neonatal plasmacytoid dendritic cells overcome intrinsic maturation defect with TLR agonist stimulation. Pediatr Res 60 (2006) 34-37
39. Wille-Reece U., Flynn B.J., Loré K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203 (2006) 1249-1258
40. Wille-Reece U., Flynn B.J., Loré K., Koup R.A., Kedl R.M., Mattapallil J.J., et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 102 (2005) 15190-15194
41. Welliver R.C., Garofalo R.P., and Ogra P.L. Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr Infect Dis J 21 (2002) 457-461
42. Haeberle H.A., Kuziel W.A., Dieterich J.-J., Casola A., Gatalica Z., and Garofalo R.P. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1α in lung pathology. J Virol 75 (2001) 878-890
43. Johnson T.R., Teng M.N., Collins P.L., and Graham B.S. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 78 (2004) 6024-6032
44. Demedts I.K., Bracke K.R., Maes T., Joos G.F., and Brusselle G.G. Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am J Respir Cell Mol Biol 35 (2006) 387-393
45. Sha Q., Truoing-Tran A.Q., Plitt J.R., Beck L.A., and Schleimer R.P. Activation of airway epithelial cells by Toll-like receptor agonists. Am J Respir Cell Mol Biol 31 (2004) 358-364
46. Guillot L., Le Goffic R., Bloch S., Escriou N., Akira S., Chignard M., et al. Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280 (2005) 5571-5580
47. Hart O.M., Athie-Morales V., O'Connor G.M., and Gardiner C.M. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175 (2005) 1636-1642
48. Johnson T.R. Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion. Expert Rev Vaccines 5 (2006) 371-380
49. Johnson T.R., Hong S., Van Kaer L., Koezuka Y., and Graham B.S. NK T cells contribute to expansion of CD8+ T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 76 (2002) 4294-4303
50. Hussell T., and Openshaw P.J.M. Intracellular IFN-γ expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 79 (1998) 2593-2601
51. Alwan W.H., Kozlowska W.J., and Openshaw P.J.M. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med 179 (1994) 81-89
52. Jones E., Price D.A., Dahm-Vicker M., Cerundolo V., and Klenerman P. The influence of macrophage inflammatory protein-1α on protective immunity mediated by antiviral cytotoxic T cells. Immunology 109 (2003) 68-75
53. Martinez-Sobrido L., Gitiban N., Fernandez-Sesma A., Mertz S.E., Jewell N.A., Hammond S., et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol 80 (2006) 1130-1139
54. Bossert B., Marozin S., and Conzelmann K.-K. Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. J Virol 77 (2003) 8661-8668
55. Graham B.S., Bunton L.A., Wright P.F., and Karzon D.T. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88 (1991) 1026-1033
56. Whyte A.L., and Miller S.C. Strain differences in natural killer cell-mediated immunity among mice: a possible mechanism for the low natural killer cell activity of A/J mice. Immunobiology 199 (1998) 23-38
57. Asselin-Paturel C., Brizard G., Pin J.J., Brière F., and Trinchieri G. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 171 (2003) 6466-6477